clinical trial · NCT06630234
A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)
Deciphera Pharmaceuticals, LLC·phase2·recruiting·n = 120
Gastrointestinal Stromal Tumor (GIST)DCC-3009
brief summary
The purpose of this Phase 1/2 master protocol study is to evaluate if DCC-3009 is safe, tolerable and works effectively in the treatment of GIST. The study will use a modular approach with each module being defined according to therapy: DCC-3009 alone or DCC-3009 in combination with other anticancer therapies. Each module will be conducted in 2 parts: Part 1 (Dose Escalation) and Part 2 (Dose Expansion). Participants will be treated in 28-day treatment cycles with an estimated duration of up to 2 years.
started
Dec 10, 2024
primary completion
May 1, 2028
completion
May 1, 2028
last updated
Feb 5, 2026
official title
A Master Protocol for the Multi-cohort, Open-label, Phase 1/2 Study of DCC-3009 in Participants With Gastrointestinal Stromal Tumor (GIST)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol